{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:25:38Z","timestamp":1788992738705,"version":"build-2803163510"},"reference-count":42,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T00:00:00Z","timestamp":1240963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Survival of children with ALL, in developing nations has not kept pace with cure rates in developed countries. Our study was designed to assess survival data and identify risk factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Data of 762 patients with ALL were analyzed. Information regarding the clinical\u2010demographic profile, therapy and course of illness were recorded. Status and duration at last follow\u2010up were utilized to generate Kaplan\u2013Meier survival curves.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean age was 5.7\u2009\u00b1\u20090.23 years (M\/F, 3.2:1). Parents of 230 (30.2%) patients opted for no therapy. There were 68 and 60 deaths in induction and remission phases respectively. Besides these, 111 children either defaulted therapy or were lost to follow up. Relapsed disease was documented in 125 cases. The 5\u2010year OS and EFS was 46% and 43% respectively. Survival analysis, using the Cox multivariate regression, for gender (<jats:italic>P<\/jats:italic>\u2009=\u20090.659, CI: 0.852\u20131.161), age (<jats:italic>P<\/jats:italic>\u2009=\u20090.943, CI: 0.725\u20131.225), symptom\u2010diagnosis interval (<jats:italic>P<\/jats:italic>\u2009=\u20090.002, CI: 1.116\u20131.668), WCC (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, CI: 1.353\u20131.814) and platelet count (<jats:italic>P<\/jats:italic>\u2009=\u20090.001, CI: 0.546\u20130.849) was performed. Bulk disease (<jats:italic>P<\/jats:italic>\u2009=\u20090.049, CI: 0.428\u20130.986), mediastinal adenopathy (<jats:italic>P<\/jats:italic>\u2009=\u20090.045, CI: 1.040\u20133.697), WCC (<jats:italic>P<\/jats:italic>\u2009=\u20090.016, CI: 1.395\u20132.691), platelet count (<jats:italic>P<\/jats:italic>\u2009=\u20090.031, CI: 0.431\u20130.967) and administration of 2 intensification blocks (<jats:italic>P<\/jats:italic>\u2009=\u20090.012, CI: 0.624\u20130.940) were found to be significant predictors of outcome by multivariate analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The management of ALL requires financial resources and access to quality supportive care. One third of our patients opted for no therapy. The other problem areas were a high proportion of therapy defaulters, lost to follow up and infection related deaths during induction and remission phases. The introduction of remedial measures for resolving the difficulties identified would hopefully improve cure rates in ALL in developing nations. Pediatr Blood Cancer 2009;53:168\u2013173. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.21897","type":"journal-article","created":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T18:01:16Z","timestamp":1241028076000},"page":"168-173","source":"Crossref","is-referenced-by-count":57,"title":["Survival outcome in childhood ALL: Experience from a tertiary care centre in North India"],"prefix":"10.1002","volume":"53","author":[{"given":"K.P.","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.","family":"Marwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Trehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,29]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390907"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05773.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1987.62"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.82.6.438"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900201)65:3 <689::AID-CNCR2820651312>3.0.CO;2-O"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.15.2001"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/sj.leu.2401555","article-title":"Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B\u2010precursor ALL","volume":"13","author":"Pullen J","year":"1999","journal-title":"Leukemia"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1976.tb00950.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2004.1.118"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2-6-374"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197811)42:5<2123::AID-CNCR2820420507>3.0.CO;2-5"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950140306"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/08880019609030819"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609051623"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.11.004"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90286-7"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0936-6555(05)80549-7"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.5.1102.1102"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197212)30:6<1534::AID-CNCR2820300619>3.0.CO;2-6"},{"key":"e_1_2_7_22_2","first-page":"1267","article-title":"Relapse patterns in Burkitt's lymphoma","volume":"32","author":"Ziegler JL","year":"1972","journal-title":"Cancer Res"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02725598"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830150105"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830390403"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008366814109"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90164-7"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/tropej\/43.3.156"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.15.2008"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1575"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909058410"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000132735.93396.92"},{"key":"e_1_2_7_34_2","first-page":"720","article-title":"Protein energy malnutrition and skeletal muscle wasting in childhood acute lymphoblastic leukaemia","volume":"37","author":"Kumar R","year":"2000","journal-title":"Ind Pediatr"},{"key":"e_1_2_7_35_2","first-page":"13","article-title":"Therapy outcome in childhood ALL","volume":"15","author":"Hiyoshi Y","year":"1985","journal-title":"Jpn J Clin Oncol"},{"key":"e_1_2_7_36_2","first-page":"61","article-title":"Prognostic factors in childhood acute lymphoblastic leukemia in Japan","volume":"72","author":"Horibe K","year":"2000","journal-title":"Int J Hematol"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.698"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830315)51:6<1041::AID-CNCR2820510612>3.0.CO;2-G"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199902)32:2<117::AID-MPO9>3.0.CO;2-9"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.18"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02723806"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0395"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401965"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.21897","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.21897","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.21897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T11:12:47Z","timestamp":1696936367000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.21897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,29]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1002\/pbc.21897"],"URL":"https:\/\/doi.org\/10.1002\/pbc.21897","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,29]]}}}